Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis

P. V. Bodhe, R. N. Kotwani, B. G. Kirodian, A. V. Pathare, A. K. Pandey, C. P. Thakur, N. A. Kshirsagar

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Efficacy and tolerability of liposomal amphotericin B (L-AMP-LRC-1; developed in India by the Liposome Clinical Pharmacology Centre, Mumbai, and the Liposome Research Centre, New Delhi) were assessed in 63 patients suffering from visceral leishmaniasis at centres in Mumbai and Patna. Patients were treated with different daily dose schedules ranging from 1 mg/kg for 21 days to 3.0 mg/kg for 7 days. L-AMP-LRC-1 was well tolerated by all 63 patients. Two patients on the 3.0 mg/kg dose developed bronchospasm on 4 occasions which reversed with standard treatment and could be prevented by increasing the duration of infusion to 3 h. Forty-three patients were freshly diagnosed cases while 20 were unresponsive to standard treatment. All 42 assessable freshly diagnosed cases responded completely to L-AMP-LRC-1 (1 patient died owing to pulmonary infection before completion of treatnent), but 5 patients required additional doses for parasitological cure. All 20 patients unresponsive to standard therapy responded completely, but 3 patients required additional doses. The regimen of 2 mg/kg daily for 10 days was 100% effective; 3 mg/kg daily for 5 days was efficacious in 90.9% freshly diagnosed patients, and 3 mg/kg daily for 7 days was effective in 100% of the unresponsive cases of visceral leishmaniasis. L-AMP-LRC-1 is thus found to be safe and effective in freshly diagnosed as well as unresponsive cases of visceral leishmaniasis at dose schedules of shorter duration than used for conventional amphotericin B.

Original languageEnglish
Pages (from-to)314-318
Number of pages5
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume93
Issue number3
DOIs
Publication statusPublished - 1999

Fingerprint

Visceral Leishmaniasis
Adenosine Monophosphate
Therapeutics
Liposomes
Appointments and Schedules
liposomal amphotericin B
Bronchial Spasm
Clinical Pharmacology
Amphotericin B
India
Lung

Keywords

  • Chemotherapy
  • India
  • Liposomal amphotericin B
  • Treatment regimens
  • Visceral leishmaniasis

ASJC Scopus subject areas

  • Parasitology
  • Medicine(all)

Cite this

Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. / Bodhe, P. V.; Kotwani, R. N.; Kirodian, B. G.; Pathare, A. V.; Pandey, A. K.; Thakur, C. P.; Kshirsagar, N. A.

In: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 93, No. 3, 1999, p. 314-318.

Research output: Contribution to journalArticle

Bodhe, P. V. ; Kotwani, R. N. ; Kirodian, B. G. ; Pathare, A. V. ; Pandey, A. K. ; Thakur, C. P. ; Kshirsagar, N. A. / Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. In: Transactions of the Royal Society of Tropical Medicine and Hygiene. 1999 ; Vol. 93, No. 3. pp. 314-318.
@article{8559dfff19864068aec6d6374d2c7822,
title = "Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis",
abstract = "Efficacy and tolerability of liposomal amphotericin B (L-AMP-LRC-1; developed in India by the Liposome Clinical Pharmacology Centre, Mumbai, and the Liposome Research Centre, New Delhi) were assessed in 63 patients suffering from visceral leishmaniasis at centres in Mumbai and Patna. Patients were treated with different daily dose schedules ranging from 1 mg/kg for 21 days to 3.0 mg/kg for 7 days. L-AMP-LRC-1 was well tolerated by all 63 patients. Two patients on the 3.0 mg/kg dose developed bronchospasm on 4 occasions which reversed with standard treatment and could be prevented by increasing the duration of infusion to 3 h. Forty-three patients were freshly diagnosed cases while 20 were unresponsive to standard treatment. All 42 assessable freshly diagnosed cases responded completely to L-AMP-LRC-1 (1 patient died owing to pulmonary infection before completion of treatnent), but 5 patients required additional doses for parasitological cure. All 20 patients unresponsive to standard therapy responded completely, but 3 patients required additional doses. The regimen of 2 mg/kg daily for 10 days was 100{\%} effective; 3 mg/kg daily for 5 days was efficacious in 90.9{\%} freshly diagnosed patients, and 3 mg/kg daily for 7 days was effective in 100{\%} of the unresponsive cases of visceral leishmaniasis. L-AMP-LRC-1 is thus found to be safe and effective in freshly diagnosed as well as unresponsive cases of visceral leishmaniasis at dose schedules of shorter duration than used for conventional amphotericin B.",
keywords = "Chemotherapy, India, Liposomal amphotericin B, Treatment regimens, Visceral leishmaniasis",
author = "Bodhe, {P. V.} and Kotwani, {R. N.} and Kirodian, {B. G.} and Pathare, {A. V.} and Pandey, {A. K.} and Thakur, {C. P.} and Kshirsagar, {N. A.}",
year = "1999",
doi = "10.1016/S0035-9203(99)90036-6",
language = "English",
volume = "93",
pages = "314--318",
journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",
issn = "0035-9203",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis

AU - Bodhe, P. V.

AU - Kotwani, R. N.

AU - Kirodian, B. G.

AU - Pathare, A. V.

AU - Pandey, A. K.

AU - Thakur, C. P.

AU - Kshirsagar, N. A.

PY - 1999

Y1 - 1999

N2 - Efficacy and tolerability of liposomal amphotericin B (L-AMP-LRC-1; developed in India by the Liposome Clinical Pharmacology Centre, Mumbai, and the Liposome Research Centre, New Delhi) were assessed in 63 patients suffering from visceral leishmaniasis at centres in Mumbai and Patna. Patients were treated with different daily dose schedules ranging from 1 mg/kg for 21 days to 3.0 mg/kg for 7 days. L-AMP-LRC-1 was well tolerated by all 63 patients. Two patients on the 3.0 mg/kg dose developed bronchospasm on 4 occasions which reversed with standard treatment and could be prevented by increasing the duration of infusion to 3 h. Forty-three patients were freshly diagnosed cases while 20 were unresponsive to standard treatment. All 42 assessable freshly diagnosed cases responded completely to L-AMP-LRC-1 (1 patient died owing to pulmonary infection before completion of treatnent), but 5 patients required additional doses for parasitological cure. All 20 patients unresponsive to standard therapy responded completely, but 3 patients required additional doses. The regimen of 2 mg/kg daily for 10 days was 100% effective; 3 mg/kg daily for 5 days was efficacious in 90.9% freshly diagnosed patients, and 3 mg/kg daily for 7 days was effective in 100% of the unresponsive cases of visceral leishmaniasis. L-AMP-LRC-1 is thus found to be safe and effective in freshly diagnosed as well as unresponsive cases of visceral leishmaniasis at dose schedules of shorter duration than used for conventional amphotericin B.

AB - Efficacy and tolerability of liposomal amphotericin B (L-AMP-LRC-1; developed in India by the Liposome Clinical Pharmacology Centre, Mumbai, and the Liposome Research Centre, New Delhi) were assessed in 63 patients suffering from visceral leishmaniasis at centres in Mumbai and Patna. Patients were treated with different daily dose schedules ranging from 1 mg/kg for 21 days to 3.0 mg/kg for 7 days. L-AMP-LRC-1 was well tolerated by all 63 patients. Two patients on the 3.0 mg/kg dose developed bronchospasm on 4 occasions which reversed with standard treatment and could be prevented by increasing the duration of infusion to 3 h. Forty-three patients were freshly diagnosed cases while 20 were unresponsive to standard treatment. All 42 assessable freshly diagnosed cases responded completely to L-AMP-LRC-1 (1 patient died owing to pulmonary infection before completion of treatnent), but 5 patients required additional doses for parasitological cure. All 20 patients unresponsive to standard therapy responded completely, but 3 patients required additional doses. The regimen of 2 mg/kg daily for 10 days was 100% effective; 3 mg/kg daily for 5 days was efficacious in 90.9% freshly diagnosed patients, and 3 mg/kg daily for 7 days was effective in 100% of the unresponsive cases of visceral leishmaniasis. L-AMP-LRC-1 is thus found to be safe and effective in freshly diagnosed as well as unresponsive cases of visceral leishmaniasis at dose schedules of shorter duration than used for conventional amphotericin B.

KW - Chemotherapy

KW - India

KW - Liposomal amphotericin B

KW - Treatment regimens

KW - Visceral leishmaniasis

UR - http://www.scopus.com/inward/record.url?scp=0032804470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032804470&partnerID=8YFLogxK

U2 - 10.1016/S0035-9203(99)90036-6

DO - 10.1016/S0035-9203(99)90036-6

M3 - Article

VL - 93

SP - 314

EP - 318

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

SN - 0035-9203

IS - 3

ER -